Phase III Study on HMPL-523 for Treatment of ITP

Primary Immune Thrombocytopenia (ITP) Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults(ESLIM-01 Study)

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP).

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled phase III clinical trial in adult patients with primary immune thrombocytopenia to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP) ;

Study Design

Related Conditions & MeSH terms

Primary Immune Thrombocytopenia (ITP)
Purpura, Thrombocytopenic, Idiopathic
Thrombocytopenia

Clinical Trial Details

NCT number	NCT05029635
Study type	Interventional
Source	Hutchmed
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	October 27, 2021
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04812483` - Immunomodulation With Eltrombopag in ITP	Phase 2
Recruiting	`NCT05338190` - Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia	Phase 3
Completed	`NCT02042560` - Study of Immune Thrombocytopenia Pathogenesis:	N/A
Recruiting	`NCT05653349` - Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)	Phase 3
Withdrawn	`NCT04274452` - A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)	Phase 3
Recruiting	`NCT05718856` - TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)	Phase 4
Recruiting	`NCT05885555` - A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies	Phase 2
Recruiting	`NCT04518475` - Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults	Phase 4